CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
nab-Paclitaxel +1 moredrug
Likely dose
nab-Paclitaxel 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02945800
NCT02945800Phase 2Completed
CompareCT.gov

Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Oct 26, 2016·Updated Apr 2, 2026

In Brief

A Phase 2 clinical trial evaluating nab-Paclitaxel and Gemcitabine for Osteosarcoma and 3 related conditions. Completed, enrolled 59 participants across 14 sites.

Detailed Summary

The purpose of this study is to see if nab-paclitaxel combined with gemcitabine prevents the formation or growth of tumors in participants with relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and other soft tissue sarcoma and to measure the length of time during and after treatment that their disease does not get worse. Researchers also want to find out if nab-paclitaxel combined with gemcitabine is safe and tolerable.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
CountriesUnited States
CollaboratorsNational Pediatric Cancer Foundation

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 26, 2016
Enrollment StartOct 25, 2016
Primary CompletionNov 19, 2024
Study CompletionFeb 17, 2025
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 9.7 years ago

Interventions

nab-Paclitaxeldrug

nab-Paclitaxel: 125 mg/m\^2 intravenously (IV)

Gemcitabinedrug

Gemcitabine: 1000 mg/m\^2 intravenously (IV)